Eli Lilly Nears $2 Billion Kelonia Acquisition to Boost CAR-T Pipeline
Eli Lilly is in advanced talks to acquire clinical-stage Kelonia Therapeutics for over $2 billion, with potential milestone-based payments and a deal possible as soon as Monday. Kelonia's CAR-T genetic medicine pipeline will bolster Lilly's cancer portfolio alongside Jaypirca, Verzenio and recent Orna Therapeutics acquisition.
1. Advanced Acquisition Talks
Eli Lilly is in advanced negotiations to acquire privately held Kelonia Therapeutics for more than $2 billion, with binding terms expected as soon as next week and additional payments contingent on development milestones.
2. Kelonia Therapeutics' CAR-T Pipeline
Boston-based Kelonia is a clinical-stage biotech developing CAR-T genetic medicines that engineer patient immune cells to target and destroy cancer cells, advancing candidates across multiple cancer indications.
3. Strategic Fit for Lilly's Oncology Portfolio
The acquisition would expand Lilly's cancer offerings beyond Jaypirca and Verzenio by adding Kelonia's gene-editing therapies, reinforcing its position in the competitive oncology market and following its Orna Therapeutics deal.
4. Financial and Timeline Considerations
The base deal exceeds $2 billion in cash, with planned milestone earnouts, and Lilly aims to finalize the transaction potentially by Monday pending regulatory and board approvals.